2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation

		Millennium Pharmaceuticals, Inc. logo. (PRNewsFoto/MILLENNIUM PHARMACEUTICALS, INC.) CAMBRIDGE, MA UNITED STATES

    CAMBRIDGE, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation
at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical
Device Conference will be webcast live and may be accessed by visiting the
Investors section of the Company's website, http://www.millennium.com. The
Company's year-end financial results for 2006 will be issued in a press
release on February 8, 2007, in conjunction with this conference.
    (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
    Dr. Deborah Dunsire, president and chief executive officer of
Millennium and Marsha Fanucci, chief financial officer and senior vice
president, corporate strategy, will discuss the Company's 2006 financial
results as well as goals and financial guidance for 2007. The presentation
will be delivered at 8:00 a.m. ET on Thursday, February 8, 2007 from The
Grand Hyatt Hotel in New York, NY. The presentation will be archived for 30
days on the Company's website http://www.millennium.com.
    About Millennium
    Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a
novel cancer product, and has a robust clinical development pipeline of
product candidates. The Company's research, development and
commercialization activities are focused in two therapeutic areas: oncology
and inflammation. By applying its knowledge of the human genome,
understanding of disease mechanisms and industrialized drug discovery
platform, Millennium is developing an exciting pipeline of innovative
product candidates. The Company's website is http://www.millennium.com.
    Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
    Contact:
    Kyle Kuvalanka
    (617)761-4734

SOURCE Millennium Pharmaceuticals, Inc.

http://www.millennium.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org PRN Photo Desk
photodesk@prnewswire.com

http://www.prnewswire.com/comp/114562.html /
CONTACT:
Kyle Kuvalanka of Millennium Pharmaceuticals,
Inc., +1-617-761-4734